PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult...
Breast Cancer Subtypes

Breast Cancer Subtypes

FOUR MOLECULAR VARIANTS EXPLAINED Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating — even for the most resilient person. Simply put, breast cancer is a complex disease. A diagnosis can be derived...
Targeting Breast Cancer

Targeting Breast Cancer

The Subtypes of Breast Cancer Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating—even for the most resilient person. Simply put, all are linked to breast cancer. Breast cancer is complex and a diagnosis...

First-in-Class: 2014 Drug Approvals

The FDA ushered in six new drugs just before the close of 2014, bringing the final tally to 41– the highest rate since 1996, when the agency approved 53 drugs. 2014 drug approvals were notable not only for their quantity, but also their quality. A number of new drugs...